Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Launched by ANTONELLO DI PAOLO, M.D., PH.D. · Jun 2, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating whether a special treatment called CMV-specific immunoglobulin can help prevent infections from a virus known as cytomegalovirus (CMV) in children who are receiving a type of stem cell transplant called allogeneic hematopoietic stem cell transplantation (HSCT). CMV can be particularly dangerous for these young patients, leading to serious complications. Researchers hope that by giving these children the immunoglobulin, they can reduce the chances of getting infected with CMV and improve their overall recovery after the transplant.

To participate in the trial, children must have undergone an allogeneic HSCT for any medical condition but cannot have had any severe reactions to immunoglobulin treatments in the past or show signs of CMV infection before starting the study. Participants will receive the immunoglobulin and be monitored to see how well it works and if it improves their transplant outcomes. The study is currently looking for participants, and it aims to gather valuable information that could help improve care for children undergoing stem cell transplants in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children who underwent allogeneic HSCT due to any condition
• Exclusion Criteria:
• • Positive personal records of immunoglobulin-related adverse reactions
• • CMV reactivation before the CMV-specific immunoglobulin prophylaxis onset
• • adoptive cellular post-HSCT immunotherapy for any indication